Case Report

Sildenafil for treatment of pulmonary hypertension in association with systemic lupus erythematosus and anti-phospholipid syndrome

Sildenafil no tratamento da hipertensão pulmonar associada a lúpus eritematoso sistêmico e síndrome antifosfolipídio

Eduardo José do Rosário e Souza, Junia Rios Garib, Nasim Michel Garib, Paulo Madureira de Pádua

J Bras Pneumol.2003;29(5):302-304

Shrinking lung syndrome in systemic lupus erythematosus

Síndrome do pulmão encolhido no lúpus eritematoso sistêmico

Cíntia Andrade Costa, Dálvaro Oliveira de Castro Jr., Sérgio Jezler, Mettermayer Santiago

J Bras Pneumol.2004;30(3):260-263

Silicosis associated with systemic lupus erythematosus

Associação de silicose e lúpus eritematoso sistêmico

Shirley Castro Holanda, Maria do Socorro T.M. Almeida, Antônio de Deus Filho

J Bras Pneumol.2003;29(4):221-224

Systemic corticosteroids as first-line treatment in pulmonary hypertension associated with POEMS syndrome

Corticoide sistêmico como tratamento de primeira linha da hipertensão pulmonar secundária a síndrome POEMS

Samia Rached, Rodrigo Abensur Athanazio, Sérvulo Azevedo Dias Júnior, Carlos Jardim, Rogério Souza

J Bras Pneumol.2009;35(8):804-808

Resolution of right-to-left shunt after primary pulmonary hypertension treatment with sildenafil

Resolução do "shunt" direita-esquerda após uso do sildenafil como tratamento de hipertensão pulmonar primária

Sérgio Marques da Silva, Carla Bastos Valeri, Humberto Bassit Bogossian, Carlos Jardim, Sérgio Eduardo Demarzo, Rogério Souza

J Bras Pneumol.2003;29(5):305-308

Original Article

Systemic effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep apnea syndrome

Efeitos sistêmicos da hipoxemia noturna em pacientes com doença pulmonar obstrutiva crônica sem síndrome da apnéia obstrutiva do sono

Paulo de Tarso Guerrero Mueller, Marcílio Delmondes Gomes, Carlos Alberto de Assis Viegas, José Alberto Neder

J Bras Pneumol.2008;34(8):567-574

Case Report

Diffuse systemic sclerosis with isolated pulmonary hypertension: a case report

Esclerose sistêmica difusa com hipertensão pulmonar isolada: relato de caso

Silméia Garcia Zanati, Katashi Okoshi, Luiz Shiguero Matsubara, Roberto Minoru Tani Inoue, Marina Politi Okoshi

J Bras Pneumol.2000;26(6):313-316

Treatment of schistosomiasis-associated pulmonary hypertension

Tratamento da hipertensão pulmonar esquistossomótica

Ricardo de Amorim Correa, Marcus Vinicius Souza Couto Moreira, Jucielle Marcelina da Silva Saraiva, Eliane Viana Mancuzo, Luciana Cristina dos Santos Silva, José Roberto Lambertucci

J Bras Pneumol.2011;37(2):272-276

Review Article

Diagnosis and treatment of pulmonary hypertension: an update*

Diagnóstico e tratamento da hipertensão pulmonar: uma atualização

Susana Hoette, Carlos Jardim, Rogério de Souza

J Bras Pneumol.2010;36(6):795-811

Brief Communication

Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension

Perda de resposta a bloqueadores dos canais de cálcio após acompanhamento prolongado em pacientes com hipertensão arterial pulmonar idiopática

Bruna Piloto1, Caio Julio Cesar dos Santos Fernandes1, Carlos Jardim1, Marcela Castro1, Jose Leonidas Alves-Jr1, Rogerio Souza1

J Bras Pneumol.2023;49(3):e20220337

Original Article

Chronic bacterial infection and echocardiographic parameters indicative of pulmonary hypertension in patients with cystic fibrosis

Infecção bacteriana crônica e indicadores ecocardiográficos de hipertensão pulmonar em pacientes com fibrose cística

Paula Maria Eidt Rovedder, Bruna Ziegler, Lilian Rech Pasin, Antônio Fernando Furlan Pinotti, Sérgio Saldanha Menna Barreto, Paulo de Tarso Roth Dalcin

J Bras Pneumol.2008;34(7):461-467

Case Report

Association of bronchogenic carcinoma with Pancoast's syndrome and acquired immunodeficiency syndrome

Associação de carcinoma broncogênico com síndrome de Pancoast e síndrome da imunodeficiência adquirida

A.C. Frohlich, D. Chiesa, M. Ronsani, L.A. Henn, S.S. Menna Barreto

J Bras Pneumol.2000;26(5):269-272

Special Article

Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension

Recomendações para o diagnóstico e tratamento da hipertensão pulmonar tromboembólica crônica da Sociedade Brasileira de Pneumologia e Tisiologia

Caio Julio Cesar dos Santos Fernandes1 , Jaquelina Sonoe Ota-Arakaki2, Frederico Thadeu Assis Figueiredo Campos3, Ricardo de Amorim Correa4, Marcelo Basso Gazzana5, Carlos Vianna Poyares Jardim1, Fábio Biscegli Jatene1, Jose Leonidas Alves Junior1, Roberta Pulcheri Ramos2, Daniela Tannus6, Carlos Teles2, Mario Terra Filho1, Daniel Waetge7, Rogerio Souza1

J Bras Pneumol.2020;46(4):e20200204

Original Article

Immunohistochemical and morphometric evaluation of COX‑1 and COX-2 in the remodeled lung in idiopathic pulmonary fibrosis and systemic sclerosis

Avaliação imuno-histoquímica e morfométrica de COX-1 e COX-2 no remodelamento pulmonar na fibrose pulmonar idiopática e na esclerose sistêmica

J Bras Pneumol.2013;39(6):692-700

Brief Communication

Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats

Tratamento com lodenafila no modelo de hipertensão pulmonar induzida por monocrotalina em ratos

Igor Bastos Polonio, Milena Marques Pagliareli Acencio, Rogério Pazetti, Francine Maria de Almeida, Bárbara Soares da Silva, Karina Aparecida Bonifácio Pereira, Rogério Souza

J Bras Pneumol.2014;40(4):421-424

Letters to the Editor

Multimodal treatment of chronic thromboembolic pulmonary hypertension: initial experience at a university hospital in southern Brazil

William Lorenzi1, Rodrigo Vugman Wainstein2, Roger Pirath Rodrigues3,4, Igor Gorski Benedetto4,5, Marcelo Basso Gazzana4,5

J Bras Pneumol.2024;50(6):e20240231

Original Article

Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia

Adaptación transcultural de la escala Cambridge Pulmonary Hypertension Outcome Review en pacientes con hipertensión pulmonar en Colombia

Claudio Villaquirán1,2,a, Socorro Moreno3,b, Rubén Dueñas4,c, Paola Acuña5,d, Juan Ricardo Lutz2,e, Jeanette Wilburn6,f, Alice Heaney6,g

J Bras Pneumol.2019;45(6):e20180332

Objective: To conduct a cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) as an instrument to evaluate the perception of symptoms, functional limitation, and health-related quality of life (HRQoL) in subjects diagnosed with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) in Colombia. Methods: The adaptation process involved 3 phases: translation, cognitive debriefing interviews, and a validation survey. To evaluate the psychometric properties, we recruited individuals ≥ 18 years of age who had been diagnosed with PAH or CTEPH to take part in the latter two stages of the adaptation process. All individuals were being followed on an outpatient basis by the pulmonary hypertension programs at Hospital Universitario San Ignacio, Fundación Clínica Shaio,and Clínicos IPS, all located in the city of Bogotá, Colombia. Results: A Spanish-language version of the CAMPHOR was developed for use in Colombia. The internal consistency was excellent for the symptoms, functioning, and quality of life scales (Cronbach's alpha coefficients of 0.92, 0.87, and 0.93, respectively). Test-retest reliability was above 0.70. The evaluation of the convergent validity and known group validity of the CAMPHOR scales confirmed that there were moderate and strong correlations with the related constructs of the Medical Outcomes Study 36-item Short-Form Health Survey, version 2, as well as showing their capacity to discriminate disease severity. Conclusions: The Spanish-language version of the CAMPHOR developed for use in Colombia was the result of a translation and cultural adaptation process that allows us to consider it equivalent to the original version, having shown good psychometric properties in the study sample. Therefore, its use to assess the impact of interventions on the HRQoL of patients with PAH or CTEPH is recommended, in research and clinical practice.

Keywords: Quality of life; Hypertension, pulmonary; Pulmonary embolism; Psychometrics.

Relationships that perceived barriers to physical activity have with functional capacity and quality of life in patients with pulmonary hypertension

Layse Nakazato Guedes de Lima1, Vitoria Veronez1, Paulo Roberto Araújo Mendes1, Tatiana Alves Kiyota1, Marcos Mello Moreira1,2, Monica Corso Pereira1

J Bras Pneumol.2025;51(1):e20240195

Objective: Barriers to physical activity can affect the functional capacity and quality of life of patients with pulmonary hypertension (PH). This study aimed to identify the main barriers to physical activity in patients with PH and to examine whether those barriers are related to functional capacity, echocardiographic variables, or quality of life. Methods: This was a cross-sectional observational study involving 70 patients. Participants scored seven potential barriers to their activities, with a score = 5 indicating a significant barrier. Participants completed the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) and Manchester Respiratory Activity of Daily Living questionnaire, as well as the six-minute walk test. Correlation analysis, univariate analysis and multiple logistic regression were performed. Results: As a perceived barrier to physical activity, 'lack of will' or 'lack of energy' was cited by 67% of the patients. The 'lack of will' barrier was found to correlate with all SF-36 domains except bodily pain. We also identified a correlation between the SF-36 vitality domain and the barriers 'lack of energy', 'lack of will' and 'lack of structure'. The logistic regression analysis indicated that the vitality domain correlated significantly with the barriers 'social influence', 'lack of energy', 'lack of will', and 'lack of structure'. For each unit decrease in the vitality score, there was a 10% increase in the probability of citing the barrier 'lack of will'. No significant correlations were identified between any of the perceived barriers and echocardiographic parameters. Conclusions: The perceived barrier most commonly reported was 'lack of will/energy', which correlated with almost all SF-36 domains, especially vitality. The 'lack of will' barrier also correlated with functional capacity.

Keywords: Pulmonary arterial hypertension; Exercise; Motivation; Quality of life; Surveys and questionnaires; Walk test.

Prevalence of pulmonary hypertension evaluated by Doppler echocardiography in a population of adolescent and adult patients with cystic fibrosis

Prevalência de hipertensão pulmonar avaliada por ecocardiografia Doppler em uma população de pacientes adolescentes e adultos com fibrose cística

Paula Maria Eidt Rovedder, Bruna Ziegler, Antônio Fernando Furlan Pinotti, Sérgio Saldanha Menna Barreto, Paulo de Tarso Roth Dalcin

J Bras Pneumol.2008;34(2):83-90

Case Report

Pulmonary tuberculosis and optical neuritis: a new association or a variation of Devic's syndrome?

Tuberculose pulmonar e neurite óptica: uma nova associação ou uma variante da síndrome de Devic?

Lucélia de Azevedo Henn, Carlos Henrique François, Ângela Beatriz John

J Bras Pneumol.1999;25(4):229-231

Search Results

Case Report

Original Article

Case Report

Review Article

Brief Communication

Original Article

Case Report

Special Article

Original Article

Brief Communication

Letters to the Editor

Original Article

Case Report

Anos

Seções

Indexes

Official publication

Newsletters